Anderson Translational Research To Advance Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Researchers at The University of Texas MD Anderson Cancer Center have uncovered a functional role for KRAS mutations in pancreatic cancer and rapidly translated these findings into a novel therapeutic approach combining a KRAS G12D inhibitor with immune checkpoint inhibitors for early- and late-stage KRAS G12D-mutant pancreatic cancer. The combination therapy led to durable tumor elimination and significantly improved survival outcomes in preclinical models, leading to the launch of a Phase I clinical trial. ....

United States , Sid Richardson , Krishnan Mahadevan , Kathleen Mcandrews , Anirban Maitra , Timothy Heffernan , Raghu Kalluri , National Cancer Institute , Anderson Translational Research To Advance Therapeutics , University Of Texas Md Anderson Cancer Center , Lustgarten Foundation , Khalifa Bin Zayed Al Nahyan Foundation , Sidw Richardson Foundation , Oncology Research , Cancer Center , Developmental Celland Cancer Cell , Cancer Biology , Translational Molecular Pathology , Translational Research , Advance Therapeutics , Developmental Cell , Cancer Cell , Therapeutics Discovery , Break Through Cancer , Khalifa Bin Zayed Al Nahyan ,